南方医科大学学报 ›› 2025, Vol. 45 ›› Issue (5): 995-1002.doi: 10.12122/j.issn.1673-4254.2025.05.12
邓悦滢1(), 耿雅雯1, 彭婷婷2, 丘峻朝3, 何丽娟4, 谢丹2, 陈姿任2, 欧阳石1,2(
), 阎升光1,5,6(
)
收稿日期:
2025-01-15
出版日期:
2025-05-20
发布日期:
2025-05-23
通讯作者:
欧阳石,阎升光
E-mail:1014564621@qq.com;ouyangshi@gzhmu.edu.cn;yansg@ncst.edu.cn
作者简介:
邓悦滢,在读硕士研究生,E-mail: 1014564621@qq.com
基金资助:
Yueying DENG1(), Yawen GENG1, Tingting PENG2, Junchao QIU3, Lijuan HE4, Dan XIE2, Ziren CHEN2, Shi OUYANG1,2(
), Shengguang YAN1,5,6(
)
Received:
2025-01-15
Online:
2025-05-20
Published:
2025-05-23
Contact:
Shi OUYANG, Shengguang YAN
E-mail:1014564621@qq.com;ouyangshi@gzhmu.edu.cn;yansg@ncst.edu.cn
摘要:
目的 对比分析慢性乙型肝炎病毒(HBV)感染孕妇与健康对照在妊娠中晚期至产后阶段的健康相关生活质量(HRQoL)差异,系统评估HBV感染对孕妇HRQoL的影响。 方法 运用前瞻性队列设计,纳入2023年4月17日~2023年9月25日在广州医科大学附属第五医院产科门诊就诊、孕周为16~24周的孕妇,每入组1例符合条件的乙肝孕妇,同时期匹配年龄、孕期、胎次相同的健康孕妇1例。最后入组70例乙肝孕妇及70例健康孕妇,分别在孕16~24周、孕32周~分娩和产后5~13周3个时间点进行动态随访及HRQoL评估。两组在各时间点的HRQoL评分比较使用t检验,采用混合线性模型分析其变化趋势,单因素方差分析和多元线性回归模型识别HRQoL降低的预测因子。 结果 在3个随访节点上,乙肝孕妇的HRQoL总评分均低于健康孕妇,同时在孕32周~分娩时两组评估得分均处于最低值。具体表现在孕32周~分娩时,乙肝孕妇组在心理分量表总分(74.27±13.43 vs 80.21±12.9,P=0.009)显著低于健康孕妇组;在产后5~13周,乙肝孕妇组在心理分量表总分(76.52±16.19 vs 85.02±6.51,P<0.001)和生理分量表得分(77.17±14.71 vs 83.09±10.1,P=0.009)显著低于健康孕妇组;乙肝病毒感染是孕妇孕晚期及产后的HRQoL降低的独立风险因子,同时自费支付医药、配偶对此次怀孕的中立态度及孕前合并其他疾病也是产后HRQoL较低的独立风险因子(P<0.05)。 结论 随着孕期负荷的加重,孕妇在孕晚期的HRQoL会出现下降,而乙肝病毒感染负向影响妊娠中晚期及产后HRQoL的生理功能和情感职能维度。在管理妊娠期的乙肝母亲时,应充分重视其HRQoL,进行及时合理的关怀及干预,有效改善其HRQoL。
邓悦滢, 耿雅雯, 彭婷婷, 丘峻朝, 何丽娟, 谢丹, 陈姿任, 欧阳石, 阎升光. 慢性乙型肝炎病毒感染影响孕妇妊娠中晚期及产后健康相关生活质量:一项前瞻性队列研究[J]. 南方医科大学学报, 2025, 45(5): 995-1002.
Yueying DENG, Yawen GENG, Tingting PENG, Junchao QIU, Lijuan HE, Dan XIE, Ziren CHEN, Shi OUYANG, Shengguang YAN. Chronic HBV infection affects health-related quality of life in pregnant women in the second and third trimesters and postpartum period: a prospective cohort study[J]. Journal of Southern Medical University, 2025, 45(5): 995-1002.
Variables | All mothers | HBV-infected mothers | Healthy mothers | t | P |
---|---|---|---|---|---|
(n=140) | (n=70) | (n=70) | |||
Mean age (SD, year) | 29.59±3.4 | 30.30±3.99 | 29.34±3.08 | 2.97 | 0.09 |
<30 | 72 (51.4) | 31 (44.3) | 41 (58.6) | 2.86 | 0.09 |
≥30 | 68 (48.6) | 39 (55.7) | 29 (41.4) | ||
Living conditions | 2.21 | 0.7 | |||
Very dissatisfied | 3 (2.1) | 1 (1.4) | 2 (2.8) | ||
Less Satisfied | 3 (2.1) | 1 (1.4) | 2 (2.8) | ||
Fair | 17 (12.1) | 11 (15.7) | 6 (8.6) | ||
More Satisfied | 41 (29.3) | 20 (28.6) | 21 (30) | ||
Most Satisfied | 76 (54.3) | 37 (52.9) | 39 (55.7) | ||
Payment method | 0.1 | 0.61 | |||
Public insurance | 3 (2.1) | 2 (2.8) | 1 (1.4) | ||
Medical insurance | 120 (85.7) | 58 (82.9) | 62 (88.6) | ||
Self-pay | 17 (12.1) | 10 (14.3) | 7 (10) | ||
Family atmosphere | 3.82 | 0.15 | |||
Fair | 9 (6.4) | 7(10) | 2 (2.8) | ||
Better | 59 (42.1) | 31 (44.3) | 28 (40) | ||
Excellent | 72 (51.4) | 32 (45.7) | 40 (57.1) | ||
As a caregiver to a patient in the family | 1.07 | 0.3 | |||
No | 131 (93.6) | 64 (91.4) | 67 (95.7) | ||
Yes | 9 (6.3) | 6 (8.6) | 3 (4.2) | ||
Working full time | 0 | 1 | |||
No | 42 (30) | 21 (30) | 21 (30) | ||
Yes | 98 (70) | 49 (70) | 49 (70) | ||
Family support | 1.87 | 0.17 | |||
No | 5 (3.6) | 4 (5.7) | 1 (1.4) | ||
Yes | 135 (96.4) | 66 (94.3) | 69 (98.6) | ||
First-born or not | |||||
No | 52 (37.1) | 21 (30) | 31 (44.3) | 3.06 | 0.08 |
Yes | 88 (62.9) | 49 (70) | 39 (55.7) | ||
Planned pregnancy | 1.26 | 0.262 | |||
No | 40 (28.6) | 17 (24.3) | 43 (61.4) | ||
Yes | 100 (71.4) | 53 (75.7) | 47 (67.1) | ||
Spouse's attitude | 2.03 | 0.363 | |||
Oppose | 1 (2.1) | 1 (1.4) | 0 (0) | ||
Support | 138 (98.6) | 68 (97.1) | 70 (100) | ||
Neutral | 1 (2.1) | 1 (1.4) | 0 (0) | ||
Nausea and vomiting in pregnancy | 3.7 | 0.3 | |||
No | 18 (12.9) | 12 (17.1) | 6 (8.6) | ||
Mild | 50 (35.7) | 24 (34.3) | 26 (37.1) | ||
Moderate | 61 (43.6) | 27 (38.6) | 34 (48.6) | ||
Severe | 11 (7.9) | 7 (10) | 4 (5.6) | ||
Other diseases before pregnancy | 0.49 | 0.17 | |||
No | 121 (83.4) | 62 (88.6) | 59 (84.3) | ||
Yes | 19 (13.6) | 8 (11.4) | 11 (15.7) | ||
complications of pregnancy | 0.15 | 0.7 | |||
No | 36 (25.7) | 47 (67.1) | 19 (27.1) | ||
Yes | 104 (74.3) | 53 (75.7) | 51 (72.9) | ||
HBeAg positive | 23 (32.9) | ||||
Antiviral treatment | 25 (35.7) | ||||
Family member infected with HBV | 33 (47.1) | ||||
HBV DNA≥2×100 000 IU/mL | 19 (21.7) |
表1 研究对象一般人口学特征
Tab.1 Demographic and clinical parameters of the participants
Variables | All mothers | HBV-infected mothers | Healthy mothers | t | P |
---|---|---|---|---|---|
(n=140) | (n=70) | (n=70) | |||
Mean age (SD, year) | 29.59±3.4 | 30.30±3.99 | 29.34±3.08 | 2.97 | 0.09 |
<30 | 72 (51.4) | 31 (44.3) | 41 (58.6) | 2.86 | 0.09 |
≥30 | 68 (48.6) | 39 (55.7) | 29 (41.4) | ||
Living conditions | 2.21 | 0.7 | |||
Very dissatisfied | 3 (2.1) | 1 (1.4) | 2 (2.8) | ||
Less Satisfied | 3 (2.1) | 1 (1.4) | 2 (2.8) | ||
Fair | 17 (12.1) | 11 (15.7) | 6 (8.6) | ||
More Satisfied | 41 (29.3) | 20 (28.6) | 21 (30) | ||
Most Satisfied | 76 (54.3) | 37 (52.9) | 39 (55.7) | ||
Payment method | 0.1 | 0.61 | |||
Public insurance | 3 (2.1) | 2 (2.8) | 1 (1.4) | ||
Medical insurance | 120 (85.7) | 58 (82.9) | 62 (88.6) | ||
Self-pay | 17 (12.1) | 10 (14.3) | 7 (10) | ||
Family atmosphere | 3.82 | 0.15 | |||
Fair | 9 (6.4) | 7(10) | 2 (2.8) | ||
Better | 59 (42.1) | 31 (44.3) | 28 (40) | ||
Excellent | 72 (51.4) | 32 (45.7) | 40 (57.1) | ||
As a caregiver to a patient in the family | 1.07 | 0.3 | |||
No | 131 (93.6) | 64 (91.4) | 67 (95.7) | ||
Yes | 9 (6.3) | 6 (8.6) | 3 (4.2) | ||
Working full time | 0 | 1 | |||
No | 42 (30) | 21 (30) | 21 (30) | ||
Yes | 98 (70) | 49 (70) | 49 (70) | ||
Family support | 1.87 | 0.17 | |||
No | 5 (3.6) | 4 (5.7) | 1 (1.4) | ||
Yes | 135 (96.4) | 66 (94.3) | 69 (98.6) | ||
First-born or not | |||||
No | 52 (37.1) | 21 (30) | 31 (44.3) | 3.06 | 0.08 |
Yes | 88 (62.9) | 49 (70) | 39 (55.7) | ||
Planned pregnancy | 1.26 | 0.262 | |||
No | 40 (28.6) | 17 (24.3) | 43 (61.4) | ||
Yes | 100 (71.4) | 53 (75.7) | 47 (67.1) | ||
Spouse's attitude | 2.03 | 0.363 | |||
Oppose | 1 (2.1) | 1 (1.4) | 0 (0) | ||
Support | 138 (98.6) | 68 (97.1) | 70 (100) | ||
Neutral | 1 (2.1) | 1 (1.4) | 0 (0) | ||
Nausea and vomiting in pregnancy | 3.7 | 0.3 | |||
No | 18 (12.9) | 12 (17.1) | 6 (8.6) | ||
Mild | 50 (35.7) | 24 (34.3) | 26 (37.1) | ||
Moderate | 61 (43.6) | 27 (38.6) | 34 (48.6) | ||
Severe | 11 (7.9) | 7 (10) | 4 (5.6) | ||
Other diseases before pregnancy | 0.49 | 0.17 | |||
No | 121 (83.4) | 62 (88.6) | 59 (84.3) | ||
Yes | 19 (13.6) | 8 (11.4) | 11 (15.7) | ||
complications of pregnancy | 0.15 | 0.7 | |||
No | 36 (25.7) | 47 (67.1) | 19 (27.1) | ||
Yes | 104 (74.3) | 53 (75.7) | 51 (72.9) | ||
HBeAg positive | 23 (32.9) | ||||
Antiviral treatment | 25 (35.7) | ||||
Family member infected with HBV | 33 (47.1) | ||||
HBV DNA≥2×100 000 IU/mL | 19 (21.7) |
Dimensions | Intervals | HBV-infected mothers Healthy mothers | t | P | |
---|---|---|---|---|---|
PF | 16-24 weeks gestation | 88.29±8.88 | 89.36±6.37 | 0.82 | 0.41 |
32 weeks gestation-Delivery | 77.68±12.94 | 83.07±8.61 | 2.9 | 0.004 | |
5-13 weeks postpartum | 88.48±10.89 | 93.52±5.87 | 3.23 | 0.002 | |
RP | 16-24 weeks gestation | 80.00±32.02 | 83.57±29.45 | 0.69 | 0.49 |
32 weeks gestation-Delivery | 67.03±36.76 | 73.57±35.07 | 1.074 | 0.29 | |
5-13 weeks postpartum | 67.75±34.06 | 80.33±27.43 | 2.3 | 0.02 | |
BP | 16-24 weeks gestation | 90.23±17.57 | 87.71±16.12 | -0.88 | 0.38 |
32 weeks gestation-Delivery | 79.12±21.31 | 80.46±17.72 | 0.4 | 0.69 | |
5-13 weeks postpartum | 79.03±20.41 | 82.3±15.77 | 1.01 | 0.31 | |
GH | 16-24 weeks gestation | 73.81±15.2 | 76.01±14.45 | 0.878 | 0.38 |
32 weeks gestation-Delivery | 73.43±14.45 | 79.12±21.31 | 1.03 | 0.3 | |
5-13 weeks postpartum | 73.43±14.97 | 76.49±13.81 | 1.24 | 0.22 | |
PCS | 16-24 weeks gestation | 83.08±13.46 | 84.25±11.01 | 0.56 | 0.57 |
32 weeks gestation-Delivery | 74.32±16.16 | 78.28±14.74 | 1.51 | 0.13 | |
5-13 weeks postpartum | 77.17±14.71 | 83.09±10.1 | 2.64 | 0.01 |
表2 研究对象在PCS及其各维度得分
Tab.2 Mean scores for different dimensions of PCS of the two groups (Mean±SD)
Dimensions | Intervals | HBV-infected mothers Healthy mothers | t | P | |
---|---|---|---|---|---|
PF | 16-24 weeks gestation | 88.29±8.88 | 89.36±6.37 | 0.82 | 0.41 |
32 weeks gestation-Delivery | 77.68±12.94 | 83.07±8.61 | 2.9 | 0.004 | |
5-13 weeks postpartum | 88.48±10.89 | 93.52±5.87 | 3.23 | 0.002 | |
RP | 16-24 weeks gestation | 80.00±32.02 | 83.57±29.45 | 0.69 | 0.49 |
32 weeks gestation-Delivery | 67.03±36.76 | 73.57±35.07 | 1.074 | 0.29 | |
5-13 weeks postpartum | 67.75±34.06 | 80.33±27.43 | 2.3 | 0.02 | |
BP | 16-24 weeks gestation | 90.23±17.57 | 87.71±16.12 | -0.88 | 0.38 |
32 weeks gestation-Delivery | 79.12±21.31 | 80.46±17.72 | 0.4 | 0.69 | |
5-13 weeks postpartum | 79.03±20.41 | 82.3±15.77 | 1.01 | 0.31 | |
GH | 16-24 weeks gestation | 73.81±15.2 | 76.01±14.45 | 0.878 | 0.38 |
32 weeks gestation-Delivery | 73.43±14.45 | 79.12±21.31 | 1.03 | 0.3 | |
5-13 weeks postpartum | 73.43±14.97 | 76.49±13.81 | 1.24 | 0.22 | |
PCS | 16-24 weeks gestation | 83.08±13.46 | 84.25±11.01 | 0.56 | 0.57 |
32 weeks gestation-Delivery | 74.32±16.16 | 78.28±14.74 | 1.51 | 0.13 | |
5-13 weeks postpartum | 77.17±14.71 | 83.09±10.1 | 2.64 | 0.01 |
Dimensions | Intervals | HBV-infected mothers Healthy mothers | t | P | |
---|---|---|---|---|---|
VT | 16-24 weeks gestation | 68.86±15.3 | 72.57±15.48 | 1.43 | 0.16 |
32 weeks gestation-Delivery | 67.46±12.45 | 70.93±12.52 | 1.636 | 0.1 | |
5-13 weeks postpartum | 66.5±15.98 | 72.28±11.54 | 2.34 | 0.02 | |
SF | 16-24 weeks gestation | 92.38±16.11 | 95.87±9.86 | 1.55 | 0.12 |
32 weeks gestation-Delivery | 89.13±15.16 | 91.9±15.47 | 1.07 | 0.29 | |
5-13 weeks postpartum | 88.29±15.61 | 97.17±6.52 | 4.14 | <0.001 | |
RE | 16-24 weeks gestation | 82.83±29.88 | 88.57±26.55 | 1.2 | 0.23 |
32 weeks gestation-Delivery | 68.07±34.48 | 84.27±25.83 | 3.14 | 0.002 | |
5-13 weeks postpartum | 77.58±33.9 | 96.15±12.31 | 4.05 | <0.001 | |
MH | 16-24 weeks gestation | 72.91±16 | 72.86±13.27 | -0.2 | 0.98 |
32 weeks gestation-Delivery | 72.41±13.76 | 73.71±12.08 | 0.6 | 0.55 | |
5-13 weeks postpartum | 73.71±13.85 | 74.49±9.04 | 0.37 | 0.71 | |
MCS | 16-24 weeks gestation | 79.27±13.93 | 82.47±11.3 | 1.49 | 0.14 |
32 weeks gestation-Delivery | 74.27±13.43 | 80.21±12.9 | 2.67 | 0.01 | |
5-13 weeks postpartum | 76.52±16.19 | 85.02±6.51 | 3.84 | <0.001 |
表3 研究对象在MCS及其各维度得分
Tab.3 Mean scores of for different dimensions of MCS in the two groups (Mean±SD)
Dimensions | Intervals | HBV-infected mothers Healthy mothers | t | P | |
---|---|---|---|---|---|
VT | 16-24 weeks gestation | 68.86±15.3 | 72.57±15.48 | 1.43 | 0.16 |
32 weeks gestation-Delivery | 67.46±12.45 | 70.93±12.52 | 1.636 | 0.1 | |
5-13 weeks postpartum | 66.5±15.98 | 72.28±11.54 | 2.34 | 0.02 | |
SF | 16-24 weeks gestation | 92.38±16.11 | 95.87±9.86 | 1.55 | 0.12 |
32 weeks gestation-Delivery | 89.13±15.16 | 91.9±15.47 | 1.07 | 0.29 | |
5-13 weeks postpartum | 88.29±15.61 | 97.17±6.52 | 4.14 | <0.001 | |
RE | 16-24 weeks gestation | 82.83±29.88 | 88.57±26.55 | 1.2 | 0.23 |
32 weeks gestation-Delivery | 68.07±34.48 | 84.27±25.83 | 3.14 | 0.002 | |
5-13 weeks postpartum | 77.58±33.9 | 96.15±12.31 | 4.05 | <0.001 | |
MH | 16-24 weeks gestation | 72.91±16 | 72.86±13.27 | -0.2 | 0.98 |
32 weeks gestation-Delivery | 72.41±13.76 | 73.71±12.08 | 0.6 | 0.55 | |
5-13 weeks postpartum | 73.71±13.85 | 74.49±9.04 | 0.37 | 0.71 | |
MCS | 16-24 weeks gestation | 79.27±13.93 | 82.47±11.3 | 1.49 | 0.14 |
32 weeks gestation-Delivery | 74.27±13.43 | 80.21±12.9 | 2.67 | 0.01 | |
5-13 weeks postpartum | 76.52±16.19 | 85.02±6.51 | 3.84 | <0.001 |
Group | 16-24 weeks gestation | 32 weeks gestation-Delivery | 5-13 weeks postpartum | F | P |
---|---|---|---|---|---|
SF-36:MCS | |||||
HBV-infected mothers | 79.27±13.93 | 74.27±13.43 | 76.52±16.19 | 3.86 | 0.23 |
Healthy mothers | 82.47±11.3 | 80.21±12.9 | 85.02±6.51 | 6.97 | <0.01 |
t | 1.49 | 2.67 | 3.84 | ||
P | 0.14 | 0.01 | <0.001 | ||
SF-36:PCS | |||||
HBV-infected mothers | 83.08±13.46 | 74.32±16.16 | 77.17±14.71 | 11.7 | <0.01 |
Healthy mothers | 84.25±11.01 | 78.28±14.74 | 83.09±10.1 | 12.68 | <0.01 |
t | 0.56 | 1.51 | 2.64 | ||
P | 0.57 | 0.13 | 0.01 |
表4 乙肝孕妇组与健康孕妇组孕期及产后HRQoL水平的对比
Tab.4 Comparison of HRQoL during pregnancy and postpartum between HBV-infected and healthy pregnant women
Group | 16-24 weeks gestation | 32 weeks gestation-Delivery | 5-13 weeks postpartum | F | P |
---|---|---|---|---|---|
SF-36:MCS | |||||
HBV-infected mothers | 79.27±13.93 | 74.27±13.43 | 76.52±16.19 | 3.86 | 0.23 |
Healthy mothers | 82.47±11.3 | 80.21±12.9 | 85.02±6.51 | 6.97 | <0.01 |
t | 1.49 | 2.67 | 3.84 | ||
P | 0.14 | 0.01 | <0.001 | ||
SF-36:PCS | |||||
HBV-infected mothers | 83.08±13.46 | 74.32±16.16 | 77.17±14.71 | 11.7 | <0.01 |
Healthy mothers | 84.25±11.01 | 78.28±14.74 | 83.09±10.1 | 12.68 | <0.01 |
t | 0.56 | 1.51 | 2.64 | ||
P | 0.57 | 0.13 | 0.01 |
Dimensions | Variables | β | Standard Error | t | P | 95% CI |
---|---|---|---|---|---|---|
MCS (32 weeks gestation-Delivery) | Working full time | -0.6 | 2.43 | -0.25 | 0.81 | -5.41, 4.21 |
HBV infected | -5.94 | 2.23 | -2.66 | 0.01 | -10.35, 1.53 | |
MCS (5-13 weeks postpartum) | Payment method=Public insurance | -6.43 | 6.91 | -0.93 | 0.35 | -20.11, 7.24 |
Payment method=Self-pay | -8 | 3.12 | -2.56 | 0.01 | -14.17, -1.82 | |
Family atmosphere | 1.23 | 1.74 | 0.71 | 0.48 | -2.22, 4.67 | |
Spouse's attitude=Oppose | 10.24 | 11.9 | 0.86 | 0.39 | -22.65, 23.99 | |
Spouse's attitude=Neutral | -28.17 | 13.81 | -2.04 | 0.04 | -13.31, 33.79 | |
Family support | 13.89 | 7.08 | 1.96 | 0.05 | -55.5, -0.84 | |
HBV infected | -6.9 | 2.13 | -3.25 | 0.001 | -11.11, -2.7 | |
PCS (5-13 weeks postpartum) | Payment method=Public insurance | 10.27 | 7.18 | 1.43 | 0.16 | -3.94, 24.48 |
Payment method=Self-pay | -8.23 | 3.19 | -2.59 | 0.01 | -14.54, -1.93 | |
Other diseases before pregnancy | -7.97 | 3.12 | -2.56 | 0.01 | -14.15, -1.8 | |
HBV infected | -6.18 | 2.16 | -2.89 | 0.01 | -10.45, -1.92 |
表5 研究对象生活质量影响因素的多元线性回归分析
Tab.5 Multivariate linear regression analysis of factors affecting the quality of life of the participants
Dimensions | Variables | β | Standard Error | t | P | 95% CI |
---|---|---|---|---|---|---|
MCS (32 weeks gestation-Delivery) | Working full time | -0.6 | 2.43 | -0.25 | 0.81 | -5.41, 4.21 |
HBV infected | -5.94 | 2.23 | -2.66 | 0.01 | -10.35, 1.53 | |
MCS (5-13 weeks postpartum) | Payment method=Public insurance | -6.43 | 6.91 | -0.93 | 0.35 | -20.11, 7.24 |
Payment method=Self-pay | -8 | 3.12 | -2.56 | 0.01 | -14.17, -1.82 | |
Family atmosphere | 1.23 | 1.74 | 0.71 | 0.48 | -2.22, 4.67 | |
Spouse's attitude=Oppose | 10.24 | 11.9 | 0.86 | 0.39 | -22.65, 23.99 | |
Spouse's attitude=Neutral | -28.17 | 13.81 | -2.04 | 0.04 | -13.31, 33.79 | |
Family support | 13.89 | 7.08 | 1.96 | 0.05 | -55.5, -0.84 | |
HBV infected | -6.9 | 2.13 | -3.25 | 0.001 | -11.11, -2.7 | |
PCS (5-13 weeks postpartum) | Payment method=Public insurance | 10.27 | 7.18 | 1.43 | 0.16 | -3.94, 24.48 |
Payment method=Self-pay | -8.23 | 3.19 | -2.59 | 0.01 | -14.54, -1.93 | |
Other diseases before pregnancy | -7.97 | 3.12 | -2.56 | 0.01 | -14.15, -1.8 | |
HBV infected | -6.18 | 2.16 | -2.89 | 0.01 | -10.45, -1.92 |
1 | Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-99. |
2 | European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy[J]. J Hepatol, 2023, 79(3): 768-828. |
3 | Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study[J]. Lancet Gastroenterol Hepatol, 2023, 8(10): 879-907. |
4 | Zhang SY, Wang FS, Zhang Z. Current advances in the elimination of hepatitis B in China by 2030[J]. Front Med, 2017, 11(4): 490-501. |
5 | Xin XN, Wang YY, Cheng J, et al. Seroepidemiological survey of hepatitis B virus infection among 764, 460 women of childbearing age in rural China: a cross-sectional study[J]. J Clin Virol, 2016, 81: 47-52. |
6 | Pan CQ, Duan ZP, Bhamidimarri KR, et al. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus[J]. Clin Gastroenterol Hepatol, 2012, 10(5): 452-9. |
7 | 刘锦锋,曾庆磊, 纪泛扑. 中国乙型肝炎病毒母婴传播防治指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40(08): 1557-66. |
8 | 尤 红, 庄 辉. 扩大慢性乙型肝炎抗病毒治疗的专家意见[J]. 中华肝脏病杂志, 2022, 30(2): 131-4. |
9 | Epstein RM, Street RL. The values and value of patient-centered care[J]. Ann Fam Med, 2011, 9(2): 100-3. |
10 | 李雁楠, 李镒冲, 张 梅, 等. 健康相关生命质量的研究进展[J]. 中华流行病学杂志, 2016, 37(9): 1311-7. |
11 | Li G, Wang G, Hsu FC, et al. Effects of depression, anxiety, stigma, and disclosure on health-related quality of life among chronic hepatitis B patients in Dalian, China[J]. Am J Trop Med Hyg, 2020, 102(5): 988-94. |
12 | Daida YG, Boscarino JA, Moorman AC, et al. Mental and physical health status among chronic hepatitis B patients[J]. Qual Life Res, 2020, 29(6): 1567-77. |
13 | Brekke M, Amro A, Småstuen MC, et al. Quality of life in Norwegian pregnant women and men with pregnant partners, and association with perception of sleep and depressive symptoms: a cross-sectional study[J]. BMC Pregnancy Childbirth, 2023, 23(1): 37. |
14 | Ishaq R, Shoaib M, Baloch NS, et al. Profile and predictors of maternal quality of life during physiological pregnancy: a cross-sectional analysis[J]. Front Public Health, 2021, 9: 801035. |
15 | Wu H, Sun W, Chen H, et al. Health-related quality of life in different trimesters during pregnancy[J]. Health Qual Life Outcomes, 2021, 19(1): 182. |
16 | 杨晓敏. 乙肝病毒感染孕妇生活质量及其相关因素研究[D]. 长沙: 中南大学, 2009. |
17 | 钟 钧, 杨舜英, 余双辉. 乙肝病毒感染孕妇心理健康状况与生活质量的调查分析[J]. 中国现代医生, 2010, 48(15): 94-5, 119. DOI: 10.3969/j.issn.1673-9701.2010.15.060 |
18 | 杨单单, 徐耀明, 赵建伟, 等. 简阳市乙型肝炎阳性孕妇生命质量评价及影响因素分析[J]. 中华疾病控制杂志, 2019, 23(3): 360-4. DOI: 10.16462/j.cnki.zhjbkz.2019.03.024 |
19 | Chen L, Yue P, Lamb KV, et al. Stigma in HBV-infected pregnant women in disclosed situations: Current status, influencing factors, and impacts on the quality of life[J]. Appl Nurs Res, 2020, 56: 151347. |
20 | OuYang S, Deng Y, Geng Y, et al. Patient-reported outcomes in mothers with chronic hepatitis B infection: a cross-sectional analysis[J]. Clin Res Hepatol Gastroenterol, 2025, 49(3): 102537. |
21 | 尤 红, 王福生, 李太生, 等. 慢性乙型肝炎防治指南(2022年版)[J]. 实用肝脏病杂志, 2023, 03(26): 457-78. |
22 | 中华医学会妇产科学分会产科学组, 中华医学会围产医学分会. 乙型肝炎病毒母婴传播预防临床指南(2020)[J]. 临床肝胆病杂志, 2020, 36(7): 1474-81. |
23 | 陈 峰. 医用多元统计分析方法[M]. 北京: 中国统计出版社, 2000. |
24 | Younossi ZM, Yu ML, Yilmaz Y, et al. Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™[J]. J Viral Hepat, 2023, 30(4): 335-44. |
25 | Zhou KN, Zhang M, Wu Q, et al. Reliability, validity and sensitivity of the Chinese (simple) short form 36 health survey version 2 (SF-36v2) in patients with chronic hepatitis B[J]. J Viral Hepat, 2013, 20(4): e47-55. |
26 | Godbole G, Irish D, Basarab M, et al. Management of hepatitis B in pregnant women and infants: a multicentre audit from four London hospitals[J]. BMC Pregnancy Childbirth, 2013, 13: 222. |
27 | Yin SM, Njai R, Barker L, et al. Summarizing health-related quality of life (HRQOL): development and testing of a one-factor model[J]. Popul Health Metr, 2016, 14(1): 22. |
28 | Fu MX, Lambert G, Cook A, et al. Quality of life in patients with HBV infection: a systematic review and meta-analysis[J]. JHEP Rep, 2025, 7(4): 101312. |
29 | Evon DM, Lin HS, Khalili M, et al. Patient-reported outcomes in a large North American cohort living with chronic hepatitis B virus: a cross-sectional analysis[J]. Aliment Pharmacol Ther, 2020, 51(4): 457-68. |
30 | 朱 萍, 赵志梅, 綦小蓉, 等. 晚孕期孕妇健康相关生命质量及其影响因素分析[J]. 中华妇幼临床医学杂志: 电子版, 2017, 13(4): 403-8. |
31 | Liu X, Wang S, Wang G. Prevalence and risk factors of postpartum depression in women: a systematic review and meta-analysis[J]. J Clin Nurs, 2022, 31(19/20): 2665-77. |
[1] | 胡嘉伟, 杜芳, 丁璐, 王路翔, 赵巍峰. 合并高血压病的乙型肝炎肝硬化患者发生肝细胞癌的风险评估:一项基于倾向性匹配评分的回顾性队列研究[J]. 南方医科大学学报, 2024, 44(11): 2243-2249. |
[2] | 唐淬蓉, 胡承光, 周宇辰, 宋杨达, 李 孟, 廖敏君, 孙家润, 钟春秀, 周 琳, 林志昭, 周元平. 乙型肝炎肝硬化合并糖尿病时发生肝细胞癌的风险:一项随访5年的前瞻性队列研究[J]. 南方医科大学学报, 2021, 41(3): 313-318. |
[3] | 李玉杰, 吴登强, 韦常宏, 杨雪佳, 周素芳. CDK1、CCNB1和NDC80与乙型肝炎相关肝细胞癌的预后和进展相关:基于生物信息学方法[J]. 南方医科大学学报, 2021, 41(10): 1509-1518. |
[4] | 赵海智, 张华军, 杨 明, 肖苍松, 王 瑶, 高长青, 王 嵘. 机器人辅助与胸骨正中切开二尖瓣置换术的生活质量及远期疗效比较[J]. 南方医科大学学报, 2020, 40(11): 1557-1563. |
[5] | 周宇辰,胡承光,袁国盛,刘俊维,任彦瑜,唐淬蓉,杨淑玲,戴琳,李园,杨定华. 抗病毒联合抗肝纤维化治疗慢性乙型肝炎肝纤维化降低肝细胞癌发生:144周的前瞻性队列研究[J]. 南方医科大学学报, 2019, 39(06): 633-. |
[6] | 肖芷琪,周福元,周彬,杨洁. 慢性乙型肝炎患者的基线丙氨酸氨基转移酶水平与抗病毒疗效的关系[J]. 南方医科大学学报, 2019, 39(02): 150-. |
[7] | 刘怡,罗碧如. 基于结构方程模型的孕妇运动行为的影响因素[J]. 南方医科大学学报, 2016, 36(11): 1514-. |
[8] | 李桃源,陈友鹏. IFN-α 2b治疗1年疗效欠佳慢性乙型肝炎患者换用恩替卡韦7年后引发HBsAg血清学转换1 例[J]. 南方医科大学学报, 2016, 36(09): 1303-. |
[9] | 陈文莉,罗鸣,陈小苹,黄晶,陈仁. 慢性乙型肝炎同病异证发病的分子机制:蛋白质组学分析[J]. 南方医科大学学报, 2016, 36(03): 410-. |
[10] | 张卡,舒欣,骆海飞,朱凤琴,曹红,徐启桓,李刚. 慢性乙型肝炎患者PBMCs中ROG、GATA3和T-bet mRNA水平及其意义[J]. 南方医科大学学报, 2016, 36(02): 186-. |
[11] | 郑少伟,Shaikh Atik Badshah,王健,蒋晖,李敏,陈国奋. 益气活血补肾法对腰椎间盘突出症术后恢复的影响[J]. 南方医科大学学报, 2015, 35(01): 137-. |
[12] | 陈建蓉,王霁,秦天强,黄艳,李静. 复方甘草酸苷治疗慢性乙型肝炎的效果及安全性的meta分析[J]. 南方医科大学学报, 2014, 34(08): 1224-. |
[13] | 曾磊,丁爱娇,江凌晓,曾静,林裕龙,袁小澎. 广州市慢性乙型肝炎患者表面抗原水平分析[J]. 南方医科大学学报, 2014, 34(07): 974-. |
[14] | 汪淑娟,高志英,卢彦平,李亚里,姜淑芳,汪龙霞,张立文. 高龄孕妇胎儿染色体非整倍体异常的早孕期检测[J]. 南方医科大学学报, 2014, 34(05): 655-. |
[15] | 张鑫,孙学华,周振华,李曼,高月求. SRC同源区2结构域蛋白基因多态性与慢性乙型肝炎易感性的关系[J]. 南方医科大学学报, 2014, 34(04): 468-. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||